Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer, Guardant Health, Adaptive Biotechnologies, and More

NEW YORK – In a Form 10-Q filed with the US Securities and Exchange Commission this week, PerkinElmer said that it reduced its headcount by 25 individuals to "realign resources to emphasize growth initiatives and integrate new acquisitions." Related to the reduction, the company took an initial restructuring or contract termination charge in its discovery and analytical solutions segment of $968,000 and in its diagnostics segment of $564,000, for a total of about $1.5 million during the quarter.

The US Food and Drug Administration said this week that it has revoked the Emergency Use Authorization for Guardant Health's Guardant-19 COVID-19 assay following a request from the company. In a statement, Guardant said that it made the decision to cease providing COVID testing and return its focus to oncology, citing the nationwide rollout of vaccines and expanded options for testing available to its customers.

Curebase and Adaptive Biotechnologies said this week that they are collaborating to broaden patient participation in Adaptive's clinical studies. The partnership initially covers two studies of Adaptive's T-Detect diagnostic test — focused on Lyme disease and COVID-19 respectively — and will utilize Curebase's decentralized clinical trial platform, which allows investigators to conduct studies across wider, more diverse populations via integration with local practitioners.

Cardinal Health said this week that it will use its distribution network to broaden access to Quidel's QuickVue At-Home OTC COVID-19 Test and Abbott's BinaxNow COVID-19 Antigen Self-Test, which allow consumers to perform tests for the virus without a prescription.

With the addition of rapid at-home tests, Cardinal Health can support customized testing and surveillance programs for workplaces, the travel and hospitality industries, and schools, the firm said. The Dublin, Ohio-based company also noted that it provides at-home tests, rapid on-site testing, PCR testing, and on-site or at-home specimen collection, among its pandemic-related offerings.

Polish diagnostics firm Genomtec said this week that it posted about PLN 1.8 million ($462,000) in revenues during the second quarter. Its revenues comprised PLN 171,000 in sales and PLN 1.6 million in other operating income, including PLN 1.55 million in grants. Operating expenses were PLN 4.7 million. The firm had an operating loss of PLN 3.0 million.

VolitionRx this week announced its second quarter financial results, including a net loss of $5.6 million. Net cash used in operating activities was $5.4 million, while grant income was approximately $400,000. The firm received approximately $900,000 from its at-the-market equity distribution program during the quarter. It ended the quarter with $27.9 million in cash and cash equivalents.

Genetics Institute of America said this week that it has received accreditation from the College of American Pathologists after passing an inspection on Aug. 10 with no deficiencies. The national laboratory, based in Delray Beach, Florida, specializes in high complexity molecular testing for research and clinical use.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.